Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade

Clinical Cancer Research

Volumn 13, Issue 22, 2007, Pages 6681-6688

  Downey, Stephanie G ^a   Klapper, Jacob A ^a   Smith, Franz O ^a   Yang, James C ^a   Sherry, Richard M ^a   Royal, Richard E ^a   Kammula, Udai S ^a   Hughes, Marybeth S ^a   Allen, Tamika E ^a   Levy, Catherine L ^a   Yellin, Michael ^b   Nichol, Geoffrey ^b   White, Donald E ^a   Steinberg, Seth M ^a   Rosenberg, Steven A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b MEDAREX INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GLYCOPROTEIN GP 100; HLA A ANTIGEN; INTERLEUKIN 2; IPILIMUMAB; STEROID;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; ARTICLE; BRAIN METASTASIS; CANCER PATIENT; CLINICAL TRIAL; CONJUNCTIVITIS; DERMATITIS; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG USE; ENTEROCOLITIS; EPISCLERITIS; FEMALE; FOLLOW UP; HEPATITIS; HUMAN; HYPOPHYSITIS; HYPOTHYROIDISM; LUNG ALVEOLITIS; MAJOR CLINICAL STUDY; MALE; MELANOMA; NEPHRITIS; PRIORITY JOURNAL; PROBABILITY; PROGNOSIS; PRURITUS; TREATMENT RESPONSE; UVEITIS; VACCINATION;

AGED; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION; FEMALE; HUMANS; MALE; MELANOMA; MIDDLE AGED; PROGNOSIS; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 36748999428     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-0187     Document Type: Article

References (37)

1. Balch CM, Atkins MB, Sober AJ. Malignant melanoma: cutaneous melanoma. In: DeVita VT, Hellman S, Rosenberg SA, editors. Cancer: principles and practice of oncology. 7th ed. Philadelphia: Lippincott-Raven Publishers; 2005. p.1754-808.
2. Rosenberg SA, Yang JC, White DE, Steinberg SM. Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2. Ann Surg 1998;228:307-19.
3. Phan GQ, Yang JC, Sherry RM, et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A 2003;100:8372-7.
4. Sanderson K, Scotland R, Lee P, et al. Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and montanide ISA 51 for patients with resected stage III and IV melanoma. J Clin Oncol 2005;23:741-50.
5. Attia P, Phan GQ, Maker AV, et al. Autoimmunity correlates with tumor regression in Patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte Antigen-4. J Clin Oncol 2005;25:6043-53.
6. Maker A, Yang JC, Sherry RM, et al. Intrapatient dose escalation of anti-CTLA-4 antibody in patients with metastatic melanoma. J Immunother 2006;29:455-63.
7. Linsley PS, Brady W, Grosmaire L, Aruffo A, Damle NK, Ledbetter JA. Binding of the B cell activation antigen B7 to CD28 costimulates T-cell proliferation and interleukin 2 mRNA accumulation. J Exp Med 1991;173:721-30.
8. Koulova L, Clark EA, Shu G, Dupont B. The CD28 ligand B7/BB1 provides costimulatory signal for alloactivation of CD4+ T cells. J Exp Med 1991;173:759-61.
9. Linsley PS, Brady W, Urnes M, Grosmair LS, Damle NK, Ledbetter JA. CTLA-4 is a second receptor for the B cell activation antigen B7. J Exp Med 1991;174:561-9.
10. Alegre ML, Frauwirth KA, Thompson CB. T-cell regulation by CD28 and CTLA-4. Nat Rev Immunol 2002;1:220-8.
11. Walunas TL, Bakker CY, Bluestone JA. CTLA-4 ligation blocks CD28-dependent T-cell activation. J Exp Med 1996;183:2541-50.
12. Krummel MF, Allison JP. CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells. J Exp Med 1996;183:2533-40.
13. Brunner MC, Chambers CA, Chan FK, Hanke J, Winoto A, Allison JP. CTLA-4-mediated inhibition of early events of T-cell proliferation. J Immunol 1999;162:5813-20.
14. Greenwald RJ, Oosterwegel MA, van derWoude D, et al. CTLA-4 regulates cell cycle progression during a primary immune response. Eur J Immunol 2002;32:366-73.
15. Shevach E. CD4+CD25+ suppressor T cells: More questions than answers. Nat Rev Immunol 2002;2:389-400.
16. Hori S, Nomura T, Sakaguchi S. Control of regulatory T-cell development by the transcription factor, foxp3. Science 2003;299:1057-61.
17. Lindsten T, Lee KP, Harris ES, et al. Characterization of CTLA-4 structure and expression on human T cells. J Immunol 1993;151:3489-99.
18. Walunas TL, Lenschow DJ, Bakker CY, et al. CTLA-4 can function as a negative regulator of cell activation. Immunity 1994;1:405-13.
19. Egen JG, Kuhns MS, Allison JP. CTLA-4: New insights into its biological function and use in tumor immunotherapy. Nat Immunol 2002;3:611-8.
20. Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science 1996;271:1734-6.
21. Hurwitz AA, Yu TF, Leach DR, Allison JP. CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma. Proc Natl Acad Sci U S A 1998;95:10067-71.
22. van Elsas A, Hurwitz AA, Allison JP. Combination immunotherapy of B16 melanoma using anti-cytoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J Exp Med 1999;190:355-66.
23. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92:205-16.
24. Agresti A. Categorical Data Analysis. New York: John Wiley and Sons, Inc.; 1990. p. 79-129.
25. Beck KE, Blansfield JA, Tran KQ, et al. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol 2006;24:2283-9.
26. Blansfield JA, Beck KE, Tran KQ, et al. Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer. J Immunother 2005;28:593-8.
27. Maker AV, Attia P, Rosenberg SA. Analysis of the cellular mechanism of antitumor responses and autoimmunity in patients treated with CTLA-4 blockade. J Immunol 2005;175:7746-54.
28. + CTLA-4high T regulatory cells with target (allo)antigen specificity. J Immunol 2004;173:2866-76.
29. Takahashi T, Tagami T, Yamazaki S, et al. Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J Exp Med 2000;192:303-10.
30. Taylor PA, Noelle RJ, Blazar BR. CD4(+) CD25(+) immune regulatory cells are required for induction of tolerance to alloantigen via co-stimulatory blockade. J Exp Med 2001;193:1311-8.
31. Waterhouse P, Penninger JM, Timms E, et al. Lymphoproliferative disorders with early lethality in mice deficient in CTLA-4. Science 1995;270:985-8.
32. Chambers CA, Sullivan TJ, Allison JP. Lymphoproliferation in CTLA-4-deficient mice is mediated by costimulation-dependent activation of CD4+ T cells. Immunity 1997;7:885-95.
33. + T cell-dependent. Blood 2006;108:3818-23.
34. Chambers CA, Kuhns MS, Egen JG, Allison JP. CTLA-4-mediated inhibition in regulation of T-cell responses: Mechanisms and manipulation in tumor immunotherapy. Annu Rev Immunol 2001;19:565-94.
35. Robinson MR, Chan CC, Yang JC, et al. CTL-associated antigen 4 blockade in patients with metastatic melanoma: A new cause of uveitis. J Immunother 2004;27:478-9.
36. Gogas H, Ioannovich J, Dafni U, et al. Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med 2006;354:709-18.
37. Smith FO, Goff SL, Klapper JA, et al. Risk of bowel perforation in patients receiving Interleukin-2 after therapy with anti-CTLA-4 monoclonal antibody. J Immunother 2007;20:130.